Skip to Content

Teleflex Inc TFX

Morningstar Rating
$227.67 +1.98 (0.88%)
View Full Chart
Unlock Our Analysis with Morningstar Investor

Company Report

Teleflex Earnings: Surgical and Interventional Products Drive Consistent Top-Line Growth

No-moat Teleflex’s third-quarter results came mostly in line with our expectations. We are maintaining our $211 fair value estimate, and the shares appear about fairly valued. Management raised its full-year revenue growth guidance to 6.4%-6.6% from 5.5%-6.3% in constant currency, mainly driven by the robust performance of surgical and interventional products. We are encouraged to see Teleflex’s top-line growth reverting to the midsingle digits after years of disruption, laying the foundation to reestablish a consistent growth profile.

Price vs Fair Value

TFX is trading at a 8% premium.
Price
$227.67
Fair Value
$185.00
Uncertainty
Medium
1-Star Price
$492.93
5-Star Price
$695.60
Economic Moat
Hjgpf
Capital Allocation
Ttn

Bulls Say, Bears Say

Bulls

UroLift provides a meaningful clinical benefit in an area of unmet need. The market opportunity is substantial, and the product could be a home-run acquisition if sales continue to grow at its current pace.

Bears

Historical acquisitions have not materially improved the company's return on capital, and the verdict is still out on management's capital allocation skill.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TFX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$225.69
Day Range
$224.11228.04
52-Week Range
$177.63276.43
Bid/Ask
$90.91 / $0.00
Market Cap
$10.70 Bil
Volume/Avg
224,061 / 309,471

Key Statistics

Price/Earnings (Normalized)
16.67
Price/Sales
3.64
Dividend Yield
0.60%
Dividend Yield (Forward)
0.60%
Total Yield
0.60%

Company Profile

Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2022 sales), interventional (16%), anesthesia (14%), surgical (14%), interventional urology (12%), original-equipment manufacturing (10%), and all other (10%). Geographic exposure for the business is primarily in the U.S., which accounts for 60% of revenue, with international markets making up the remainder.
Sector
Healthcare
Industry
Medical Instruments & Supplies
Stock Style Box
Mid Core
Total Number of Employees
15,500

Competitors

Valuation

Metric
TFX
BSX
COLO B
Price/Earnings (Normalized)
16.6728.7935.43
Price/Book Value
2.484.3510.24
Price/Sales
3.645.946.94
Price/Cash Flow
17.1729.9033.20
Price/Earnings
TFX
BSX
COLO B

Financial Strength

Metric
TFX
BSX
COLO B
Quick Ratio
2.230.670.37
Current Ratio
3.581.420.61
Interest Coverage
7.058.0710.27
Quick Ratio
TFX
BSX
COLO B

Profitability

Metric
TFX
BSX
COLO B
Return on Assets (Normalized)
6.39%8.56%12.66%
Return on Equity (Normalized)
10.88%15.65%53.76%
Return on Invested Capital (Normalized)
8.48%10.89%17.62%
Return on Assets
TFX
BSX
COLO B

Medical Instruments & Supplies Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
ISRG
Intuitive Surgical IncZxkp$111.0 Bil
BDX
Becton Dickinson & CoSktjfqg$69.2 Bil
ALC
Alcon IncGsqfvs$37.0 Bil
CLPBY
Coloplast A/S ADRJgbsb$26.1 Bil
WST
West Pharmaceutical Services IncHhl$26.0 Bil
RMD
ResMed IncJhtnc$23.5 Bil
BAX
Baxter International IncMpzhs$18.5 Bil
HOLX
Hologic IncYhnvxm$17.1 Bil
COO
The Cooper Companies IncZmcjm$16.9 Bil